Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Under the agreement, Labcorp will manage Graves Gilbert's main full-service laboratory in Bowling Green, Kentucky and its facility in Glasgow, Kentucky.

Samples for the validation will be collected at the Catholic University of Korea and will represent people across all stages of Alzheimer's disease.

NEW YORK – Roche on Wednesday announced that it has received CE marking for its new mass spectrometry solution comprising the Cobas I 601 analyzer and Ionify reagent pack of four tests for steroid ...